ImmunoGen’s Elahere Wins Big In Confirmatory Ovarian Cancer Trial

The company called MIRASOL’s reported OS benefit unprecedented and is gearing up to file for full FDA approval as well as EMA approval.

ImmunoGen announced data from the Phase III MIRASOL trial of Elahere in ovarian cancer • Source: Shutterstock

ImmunoGen, Inc. chalked up a clear victory in the confirmatory Phase III MIRASOL trial of Elahere (mirvetuximab soravtansine-gynx) among pretreated patients with folate receptor alpha (FRα)-positive platinum chemotherapy-resistant ovarian cancer, as the drug became the first to demonstrate an overall survival (OS) advantage in that population. The company sees the data as enabling it to extend the drug’s reach into Europe while also building confidence in its ability to expand into other ovarian cancer subpopulations.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D